Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma

Liver International

Volumn 36, Issue 5, 2016, Pages 737-745

  Lo, Jessica ^a,b   Lau, Eunice Yuen Ting ^a,b   So, Francis Tak Yuk ^a,b   Lu, Ping ^a,b   Chan, Vera Sau Fong ^b   Cheung, Vincent Chi Ho ^a,b   Ching, Rachel Hiu Ha ^a,b   Cheng, Bowie Yik Ling ^a,b   Ma, Mark Kin Fai ^a,b   Ng, Irene Oi Lin ^a,b   Lee, Terence Kin Wah ^a,b  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CD47; Chemoresistance; HCC

Indexed keywords

ANTINEOPLASTIC AGENT; B 6H 12; CD47 ANTIGEN; CISPLATIN; DOXORUBICIN; MESSENGER RNA; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CD47 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL MIGRATION; CELL SELF-RENEWAL; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; LIVER TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CD47 ANTIGEN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOXORUBICIN; HUMANS; LIVER NEOPLASMS; MACROPHAGES; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84963964074     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12963     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
3. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
4. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007; 445: 106-10.
5. Lee TK, Cheung VC, Lu P, et al. Blockade of CD47 mediated CTSS-PAR2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014; 60: 179-91.
6. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010; 142: 699-713.
7. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138: 286-99.
8. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106: 14016-21.
9. Edris B, Weiskopf K, Volkmer AK, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 2012; 109: 6656-61.
10. Kim D, Wang J, Willingham SB, et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012; 26: 2538-45.
11. Chao MP, Tang C, Pachynski RK, et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 2011; 118: 4890-901.
12. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIPRα) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012; 109: 6662-7.
13. Tseng D, Volkmer JP, Willingham SB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophage primes an effective antitumor T-cell response. Proc Natl Acad Sci USA 2013; 110: 11103-8.
14. Xiao Z, Chung H, Banan B, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett 2015; 360: 302-9.
15. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-56.
16. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in HCC. Cancer Res 2007; 67: 10831-9.
17. Uluçkan O, Becker SN, Deng H, et al. CD47 regulates bone mass and tumor metastasis to bone. Cancer Res 2009; 69: 3196-204.
18. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 2009; 1: 3ra7.
19. Tsai RK, Discher DE. Inhibition of 'self' engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 2008; 180: 989-1003.
20. Wang Y, Xu Z, Guo S, et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther 2013; 21: 1919-29.
21. Zhao XW, van Beek EM, Schornagel K, et al. Cd47-signal regulatory protein-alpha (sirpalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA 2011; 108: 18342-7.